Literature DB >> 1720089

1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts.

S H Scharla1, D D Strong, S Mohan, D J Baylink, T A Linkhart.   

Abstract

1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] induces differentiation and inhibits proliferation in many cell types including bone cells. These effects may be mediated by the modulation of the insulin-like growth factor (IGF) regulatory system. Therefore we investigated the effects of 1,25-(OH)2D3 on transcript and protein levels of both IGF-I and IGF binding proteins (IGFBPs) in clonal mouse osteoblasts. Subconfluent cultures were treated in serum-free medium with 1,25-(OH)2D3. Secreted IGF-I was measured using a RIA under conditions eliminating the interference of IGFBPs. 1,25-(OH)2D3 (10(-11)-10(-8) M) inhibited IGF-I release in a dose dependent manner at 24 h (maximally to 30 +/- 5% of control, mean +/- SEM of seven independent experiments). In a time course study IGF-I increased in the media of control cultures over a 48-h period, while IGF-I secretion was completely prevented from 6 h onward in 1,25-(OH)2D3 treated cultures. Northern blot analysis revealed four IGF-I transcripts of 0.9, 1.8, 4.4, and 7.5 kilobases (kb). 1,25-(OH)2D3 decreased levels of the 7.5 kb IGF-I transcript from 4-48 h, with maximal inhibition occurring at 24 h (25% of control). Western ligand blots of the culture medium demonstrated secretion of a 25-kilodalton IGFBP, which comprised greater than or equal to 90% of the secreted IGFBPs. The 25-kilodalton IGFBP had previously been shown to have sequence similarity with IGFBP-4, a binding protein which inhibits the action of IGFs on bone cells. 1,25-(OH)2D3 treatment increased secretion of IGFBP-4 up to 14-fold over 24 h. 1,25-(OH)2D3 also increased IGFBP-4 (2.2 kb) transcript levels within 30 min, with the maximal stimulation of 8-fold occurring after 8 h. [3H]Thymidine incorporation into cells was inhibited by 1,25-(OH)2D3 both under basal and serum-stimulated conditions. Our results are consistent with the hypothesis that the effects of 1,25-(OH)2D3 on osteoblast proliferation may be mediated in part by decreased levels of IGF-I and increased concentrations of inhibitory IGFBP-4. It is proposed that this alteration in the IGF system may be an important functional autocrine or paracrine switch in the transition of osteoblasts from states of proliferation to differentiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720089     DOI: 10.1210/endo-129-6-3139

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

Review 1.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

2.  Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects.

Authors:  F Bogazzi; G Rossi; M Lombardi; L Tomisti; C Sardella; L Manetti; O Curzio; C Marcocci; L Grasso; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

3.  Research resource: whole transcriptome RNA sequencing detects multiple 1α,25-dihydroxyvitamin D(3)-sensitive metabolic pathways in developing zebrafish.

Authors:  Theodore A Craig; Yuji Zhang; Melissa S McNulty; Sumit Middha; Hemamalini Ketha; Ravinder J Singh; Andrew T Magis; Cory Funk; Nathan D Price; Stephen C Ekker; Rajiv Kumar
Journal:  Mol Endocrinol       Date:  2012-06-25

4.  Lactoferrin promote primary rat osteoblast proliferation and differentiation via up-regulation of insulin-like growth factor-1 expression.

Authors:  Jian-ming Hou; Man Wu; Qing-ming Lin; Fan Lin; Ying Xue; Xu-hua Lan; En-yu Chen; Mei-li Wang; Hai-yan Yang; Feng-xiong Wang
Journal:  Mol Biol Rep       Date:  2014-05-03       Impact factor: 2.316

5.  Vitamin D metabolism and action in human bone marrow stromal cells.

Authors:  Shuanhu Zhou; Meryl S LeBoff; Julie Glowacki
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

6.  Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D(3) stimulation.

Authors:  N Maruotti; A Corrado; M Grano; S Colucci; F P Cantatore
Journal:  Rheumatol Int       Date:  2008-11-07       Impact factor: 2.631

7.  Exogenous prostacyclin, but not prostaglandin E2, produces similar responses in both G6PD activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture.

Authors:  S C Rawlinson; S Mohan; D J Baylink; L E Lanyon
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

Review 8.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

9.  Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies.

Authors:  Flor M Pérez-Campo; Tobias May; Jeannette Zauers; Carolina Sañudo; Jesús Delgado-Calle; Jana Arozamena; María T Berciano; Miguel Lafarga; José A Riancho
Journal:  J Bone Miner Metab       Date:  2016-04-02       Impact factor: 2.626

Review 10.  Role of IGF1 and EFN-EPH signaling in skeletal metabolism.

Authors:  Richard C Lindsey; Charles H Rundle; Subburaman Mohan
Journal:  J Mol Endocrinol       Date:  2018-03-26       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.